Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases

Philippe Georgel

Abstract: Interleukin-1β (IL-1β) and type I interferons (IFNs) are major cytokines involved in autoinflammatory/autoimmune diseases. Separately, the overproduction of each of these cytokines is well described and constitutes the hallmark of inflammasomopathies and interferonopathies, respectively. While their interaction and the crosstalk between their downstream signaling pathways has been mostly investigated in the frame of infectious diseases, little information on their interconnection is still available in the context of autoinflammation promoted by sterile triggers. In this review, we will examine the respective roles of IL-1β and type I IFNs in autoinflammatory/rheumatic diseases and analyze their potential connections in the pathophysiology of some of these diseases, which could reveal novel therapeutic opportunities.

Keywords: inflammation; type I interferons; interleukin-1β; crosstalk

1. Introduction

Numerous reports have documented the roles of IL-1β and type I interferons (IFNs) in the defense mechanisms that are engaged upon bacterial (such as M. tuberculosis [1]) and viral [2] infections. Type I (and type III) IFNs exert powerful antiviral activities that have been extensively described [3,4], while those mediated by IL-1β are more scarcely defined [5]. Furthermore, the interplay of these cytokines and their downstream signaling pathways has also been largely explored during infectious diseases [6]. COVID-19 being the most recent example [7].

These cytokines are produced following the activation of dedicated pattern-recognition receptors (PRRs) [8] in response to specific pathogens and the associated molecular patterns (PAMPs) that they express. Interestingly, the same PRRs (nucleotide-binding oligomerization domain-like receptors—NLRs, Toll-like receptors—TLR or AIM2-like receptors—ALRs) are also activated upon the detection of danger signals (DAMPs [9–11]) produced in sterile conditions. In this case, inflammation, instead of creating the appropriate conditions to clear off an invading pathogen, generates tissue damage and evolves towards detrimental endpoints for the host. First, this review will provide some examples of autoimmune/autoinflammatory diseases that are caused by the deregulated expression of type I IFNs and IL-1β. Indeed, these cytokines are major mediators of inflammation and can be incriminated in many cytokinopathies [12], which are diseases caused by alterations in a single gene affecting cytokines expression. Several examples of interferonopathies and inflammasomopathies will illustrate these cases. Additionally, type I IFNs and IL-1β perturbations can also result from interactions between many genes and the host environment. Lupus, a disease in which patients exhibit an “IFN signature” [13] (i.e., overexpression of a subset of IFN-stimulated genes) and Alzheimer’s disease, during which IL-1β is known to be overexpressed [14], will serve as examples for such complex (multigenic/multifactorial) diseases in which these cytokines are involved. Next, we will analyze several cases where...
reciprocal interactions between them have been observed, and the therapeutic perspectives that have been derived from these observations. Multiple sclerosis, a disease treated with IFN-β (among other therapeutic options) and which is also characterized by increased IL-1β expression, will be described. In parallel, gout and rheumatoid arthritis (RA) are joint inflammatory diseases in which reducing IL-1β overexpression can represent an efficient therapeutic opportunity. Interestingly, promoting type I IFNs expression recently appeared as an attractive way to dampen IL-1β production in animal models for gout and RA [15,16]. These examples in which type I IFNs and IL-1β exert a reciprocal control will reveal novel options to treat patients suffering from these inflammatory diseases, whose general features are given in Table 1. Finally, innovative cell culture methods designed to investigate and aimed at deciphering these interactions between cytokines at the molecular and cellular levels will be discussed in a prospective chapter.

Table 1. Type I IFNs- and IL-1β-mediated pathologies discussed in this review.

| Disease                                      | Type                          | Genetic Defect      | Cytokine Profile                          | Treatment                      |
|----------------------------------------------|-------------------------------|---------------------|------------------------------------------|--------------------------------|
| STING-associated vasculopathy with onset in infancy (SAVI) | interferonopathy             | STING gain-of-function | excessive type I IFN secretion           | corticosteroids jakinhibs (clinical trials) |
| Systemic Lupus Erythematosus (SLE)           | rheumatic autoimmune/autoinflammatory disease | multifactorial disease | IFN signature (overexpression of IFN-stimulated genes) | corticosteroids Immunosuppressants (e.g., methotrexate) biologics (e.g., antiB-cell mAb) |
| Familial Mediterranean Fever (FMF)           | inflammasomopathy             | mutations in MEFV (Mediterranean fever, also named PYrin) | constitutive IL-1β secretion           | colchicin biologics (IL-1β receptor antagonist, anti IL-1β mAb) |
| Alzheimer’s disease (AD)                     | Neurodegenerative disease     | multifactorial disease | excessive IL-1β, IL-6 and TNF secretion | Cholinesterase inhibitors N-methyl D-aspartate (NMDA) antagonists anti amyloid-β mAb (clinical trials) |
| Gout                                         | rheumatic autoinflammatory disease | multifactorial disease | excessive IL-1β secretion                | colchicin biologics (IL-1β receptor antagonist, anti IL-1β mAb) |
| Rheumatoid Arthritis (RA)                    | rheumatic autoimmune/autoinflammatory disease | multifactorial disease | TNF overexpression IL-1β overexpression IFN signature (overexpression of IFN-stimulated genes) | corticosteroids Immunosuppressants (e.g., methotrexate) biologics (e.g., anti TNF mAb) |
| Multiple sclerosis (MS)                      | inflammatory, neurodegenerative disease | multifactorial disease | increased IFNγ, IL-12, IL-17 secretion/activation | IFN-β biologics (e.g., antiB-cell mAb) |

2. Type I IFNs in Autoinflammation

Since their initial discovery in 1957 [17], type I IFNs have been essentially considered beneficial with regards to their unique antiviral activities [18]. More recently, however, it appeared that the deregulated and inappropriate expression of these cytokines could be harmful. Indeed, in the absence of any obvious viral trigger, the overexpression of type I IFNs was noted in patients suffering from inflammatory disorders [19], some of which were caused by single-gene mutations (monogenic diseases), while others are classified within complex diseases, i.e., requiring environmental factors and many specific genetic
alterations to promote pathogenic features. STING-associated vasculopathy with onset in infancy (SAVI) belongs to the first category of ailments and is caused by a gain-of-function mutation in the STING gene; this gene encodes a protein that is at the cross-roads between the cGAS (cyclic GMP-AMP synthase, an exogenous DNA sensor) and the interferon regulatory factors (IRFs)-3 and -7, which induce type I IFN transcription [20]. In these patients, TANK-binding kinase (TBK1) is constitutively activated in the absence of viral RNA, leading to spontaneous and massive type I IFN production. Fortunately, Janus kinase inhibitors might be promising drugs to block the signaling pathway downstream of the type I IFNs receptor (IFNAR) and provide relief to a subset of patients with SAVI syndrome [21]. In past years, many additional genetic origins of type I interferonopathies were elucidated following whole-exome sequencing in patients and controls in families affected by these rare symptoms [22,23].

On the other hand, systemic lupus erythematosus (SLE), with the exception of childhood-onset SLE, is a complex disease driven by a combination of genetic, epigenetic and environmental factors [24]. Of note, a hallmark of SLE is the so-called “IFN signature”, describing the overexpression of IFN-stimulated genes (ISGs) in circulating mononuclear blood cells or target tissues [25]. Of note, the level of ISGs expression appears correlated with disease severity [26]. Interestingly, ISGs overexpression is also observed in other inflammatory diseases, such as rheumatoid arthritis [13]. More recently, single-cell RNAseq technology enabled a precise description of gene expression in SLE patients that appeared to form a more heterogeneous population than previously suspected [27]. Such stratification of patients with multiOMICs technologies already sets the grounds for more targeted, individualized therapies [28]. In the frame of the present review, it is noteworthy to observe that, in addition to type I IFNs, IL-1 family member expression can also be used as a biomarker in SLE patients [29]. Finally, severe complications occurring in lupus patients, such as macrophage activation syndrome or pericarditis, have been successfully reduced with anakinra, an IL-1b antagonist [30,31], showing that both IFNs-I and IL-1 participate in lupus pathogenesis, at least in a subset of patients.

3. IL-1β in Autoinflammation

Similar to type I IFN-dependent diseases, many inflammatory syndromes result from uncontrolled IL-1β expression. Among them, inflammasomopathies are a group of monogenic diseases caused by hereditary defects in inflammasomes components. Inflammasomes are intracellular multiprotein complexes composed of a sensor (detecting pathogen-associated molecules, such as peptidoglycans from Gram-positive bacteria or sterile components, such as silicate or urate crystals), an adaptor (ASC for apoptosis-associated speck-like protein containing a caspase recruitment domain) and the Caspase 1. Following multimerization of this complex, activated Caspase 1 cleaves pro IL-1β into its mature, bioactive form, which is exported out of the cell through pores formed by GasderminD [32]. The prototypical inflammasomopathy with periodic fever is familial mediterranean fever (FMF), a disease caused by mutations in the MEFV (mediterranean fever) gene encoding the protein PYRIN, which is part of the inflammasome complex. Gain-of-function mutations in the MEFV gene lead to increased Caspase 1 activation and IL-1β levels [33]. The development of IL-1β antagonists has considerably improved the management of these patients [34].

In addition to these monogenic inflammatory diseases, emerging evidence suggests that IL-1β is also involved in complex neurological disorders, such as Alzheimer’s disease (AD) [35]. Indeed, AD occurrence depends on many factors, such as age, comorbidities, genetics and education level. However, a strong correlation between AD and reactive oxygen species (ROS) production has been evidenced, where ROS are major inducers of NLRP3-dependent IL-1β production [36], including in neurons [37]. Importantly, this observation has led to novel therapeutic options for neurodegenerative disorders affecting an increasing number of patients worldwide.
4. Interplay between Type I IFNs and IL-1β in Inflammatory/Autoimmune Diseases

Whilst interferonopathies and inflammasomopathies may appear as very divergent or even antagonistic inflammatory diseases (although an overlap can be observed in some instances, as mentioned in the previous chapters), the pathogenesis of some inflammatory conditions clearly involves both type I IFNs and IL-1β. Multiple sclerosis (MS) belongs to this category, since IL-1β is strongly implicated in this inflammatory, neurodegenerative disease [38], and IFN-β is still a classical first-line therapy [39], although rituximab (an anti-CD20 monoclonal antibody designed to induce B cell ablation) was shown recently as a promising option [40]. Low STING-dependent type I IFNs expression in peripheral blood mononuclear cells (PBMC) isolated from MS patients [41] is in agreement with these observations.

The mechanism by which IFN-β exerts its anti-inflammatory actions has been partially elucidated [42]. It is now very clear that type I IFNs promote IFNAR-dependent IL-1Ra (encoding an antagonist of the IL-1β receptor) and IL-10 gene expressions. Furthermore, type I IFNs and IL-10 were recently shown to negatively regulate the activation of the NLRP3 inflammasome in a STAT3-dependent manner [43–45]. These data support the notion that IL-1β and type I IFNs exert antagonistic activities that have been experimentally tested in various inflammatory settings (collagen-induced arthritis, allotransplant rejection), whereby the beneficial administration of type I IFNs has been documented.

Reduced expression of NLRP3 was also shown to participate in the anti-inflammatory benefits of type I IFNs in MS [46,47]. This observation also likely accounts for the spectacular therapeutic potential of imiquimod, a TLR7 agonist and strong inducer of type I IFNs, which we observed in a mouse model of acute uratic inflammation [15]. Importantly, our work using this mouse model of gout as well as RA models [16] enabled us to develop a framework in which complex cellular interactions are required to account for the counter-regulatory effects mediated by type I IFNs on IL-1β [48]. Future work using elaborate cell culture systems will be necessary to decipher this cellular dialog, as discussed below. Surprisingly, the regulatory roles of IL-1β on type I IFNs and ISGs expression are more scarcely documented [49], and these experimental cell culture experiments would also be useful to explore this issue. In this regard, the recent observation that IL-1β promotes type I IFN and ISGs expression in bone marrow-derived dendritic cells (BMDC) appears of particular interest [6]. A schematic network of type I IFNs and IL-1β interactions is depicted in Figure 1.

**Figure 1.** Schematic network of interactions between type I IFNs and IL-1β. Pathogens- or danger-associated molecular patterns (PAMPs, DAMPs) interact with their cognate pattern recognition receptor (PRRs). In the example shown here, DNA binding and activation of the cGAS/STING pathway leads to type I interferons (IFNs) secretion, while monosodium urate (MSU) crystals activate the NLRP3 inflammasome, which induces IL-1β release. In most cases, both cytokines exert antagonistic activities, mutually repressing their expression levels by various mechanisms.
5. Therapeutic Consequences

As mentioned above, some overlap may exist between IL-1β and type I IFNs in various inflammatory settings, opening novel therapeutic opportunities.

5.1. Targeting Type I IFNs in IL-1β-Dependent Diseases

Type I IFNs-based therapies were developed long ago and were particularly useful in hepatitis C virus-infected patients, despite considerable side effects [50]. In this regard, our strategy to perform epicutaneous application of a cream containing imiquimod, a powerful promoter of IFN synthesis to treat inflamed joints of RA or gout mice, appeared as a promising approach to avoid adverse reactions [15,16]. Importantly, we observed a drastic reduction in neutrophils in the cellular infiltrate following imiquimod application, which also certainly participates in the reduced local inflammation through the limitation of ROS production. Topical imiquimod has been used for 20 years in humans to treat genital warts and skin carcinoma [51]; its pharmacokinetics and precautions for use are well known. Therefore, we believe that our pre-clinical studies advocate for using this drug to treat joint inflammation in RA or gout patients, as well as localized skin inflammation, showing evidence of a massive neutrophilic infiltrate (neutrophilic dermatoses). On the other hand, strategies presently in use or under development aim at reducing the IFN-dependent signaling pathway, for instance, in SLE patients with anifrolumab, a monoclonal antibody targeting the type I IFN receptor subunit 1 [52]. Other tools to reduce IFN signaling are the Janus kinase (JAK) inhibitors (jakinhibs), a novel family of compounds effective in myeloproliferative or autoimmune (such as RA) diseases [53]. Given their antagonism, a rise in IL-1β can be expected in patients with reduced type I IFN production as a result of treatment with anifrolumab or jakinhibs, which might require specific attention, and possibly the need for additional anti-IL-1β therapy.

5.2. Targeting IL-1β in Interferonopathies

Jakinhibs are the most promising therapeutic opportunities for patients afflicted by type I interferonopathies [54]. As mentioned above, following IL-1β expression levels might be critical in these critically ill patients.

In addition, IL-1β inhibition might also represent a useful strategy in various inflammatory diseases, including interferonopathies. Indeed, this cytokine is also expressed in the central nervous system, where it mediates pain [55]. Supporting this notion is the observation that psoriatic arthritis (PsA) patients treated with anti-TNF antibodies still experience pain, while joint inflammation is concomitantly reduced [56]. In these patients, and possibly in others treated with TNF inhibitors or more generally experiencing pain as a result of inflammatory reactions, there might be room for IL-1β blockers (canakinumab, anakinra). Finally, it is interesting to note that experiments in the experimental autoimmune encephalomyelitis (EAE) mouse model support the therapeutic potential of IL-1 blockade in MS [57], an approach that has been tested in a very limited number of patients suffering colchicine-resistant familial mediterranean fever (FMF, an inflammasomopathy) and MS [58]. Strikingly, MS symptoms were markedly reduced in these patients.

Altogether, these observations indicate that the management of patients suffering inflammatory symptoms might require a combination of drugs targeting various players involved in the pathogenesis of these diseases. Future work aiming at a better characterization of the interplay between these players is needed to provide more efficient and targeted therapeutic approaches. Some insights aiming at this goal are suggested in the perspectives and conclusions of the present review.

6. Perspectives

Although several molecular interactions between type I IFNs and IL-1β have been described (transcriptional induction of IL-1Ra and IL-10 genes upon IFN-β treatment [42]; and reciprocally, increased transcription of IFN-β and ISGs following IL-1β addition in the culture medium of BMDCs [6]), most studies have been performed in cell cultures
where one cell type only has been investigated (dendritic cell, monocytes/macrophages, etc.). This constitutes a fundamental weakness, since these cytokines are produced by different cell types (neutrophils [59], eosinophils [60]) interacting in a specific microenvironment. To gain access to more physiological interactions at the cellular and molecular levels, co-cultures, either in two-dimension systems (Boyden chambers) or even using more complex organoids, need to be developed [61]. As seen in Figure 2, considering only type I IFNs (IFN-α/β) and IL-1β and the five main immune cell types that are able to produce them, upon the TLR7-dependent stimulation (with imiquimod, IMQ) of pDCs, an already complex network of interactions is created, in which the reciprocal effects of these cytokines are presently totally unknown and certainly quite different from what can be observed in monotypic cell cultures. Producing mixed cultures in Boyden chambers (which has been previously performed [62]) could be a good starting point, in which each cell type (for instance, pDC and macrophages, or pDC and neutrophils) could be investigated separately after cell sorting with high-throughput technologies (RNAseq) and analyzed morphologically (apoptosis, NETosis, polarization) in various conditions driving cytokine (type I IFNs or IL-1β) synthesis. Such approaches might be instrumental to better characterize, at the cellular level, the recently described interaction between IL-1β-dependent mitochondrial DNA release and cGAS/STING-dependent type I IFNs secretion [63]. In the future, spheroids or organoids might add complexity to the system by adding support cells such as keratinocytes or fibrocytes and extracellular matrix components.

![Figure 2. The complex network of interactions between type I IFNs, IL-1β and the cells that produce them. Simplified representation of the potential interactions between plasmacytoid (pDC) or conventional (cDC) dendritic cell, macrophages/monocytes, neutrophils and eosinophils upon, for example, imiquimod (IMQ) stimulation acting via TLR7 in pDCs. Blue arrows denote cytokine expression, red arrows indicate that these cytokines exert an effect (activation or inhibition) on target cells and green arrows represent retro-control of the cytokines on the cells that produce them.](image)

7. Conclusions

We have merely touched on the complexity of inflammation here by analyzing the reciprocal interactions of two cytokines. Despite the paramount importance of IL-1β and type I IFNs in autoinflammatory diseases, many other cytokines, among which TNF are self-evident, can certainly not be neglected. In 2006, Banchereau and Pascual published a seminal paper in which they extended the Th1/Th2 concept into a “compass of immunity and immunopathology” organized into two perpendicular axes: one defined by the reciprocal interactions of IFN-α and TNF and the other by IL-4 and IFN-γ [64]. Accord-
ing to this model, SLE was identified by an overexpression of IFN-α. Fifteen years later, high-throughput technologies have evidenced the heterogeneity of patients suffering from complex diseases such as SLE or RA, which are now defined as pathotypes [65]. Because some cytokines are direct drivers of immunopathology and because the quantification of most cytokines is easily feasible with multiplex technology, we suggest that providing an extensive profiling of cytokines (in the blood or the affected tissue if accessible), a “cytokinome” as suggested by others [66], would be a useful tool to better define patients sub-groups by comparison with a reference of healthy subjects [67]. This approach, illustrated by the “multidimensional compass” illustrated in Figure 3, would also be instrumental in defining the best therapeutic option for a patient, following its impact on the normalization of its cytokine profile and eventually adjusting it. In this example, two RA patients are identified by increased TNF expression compared to a control group (with the reference cytokinome resulting from a set of healthy donors) with variables (age, sex, etc.) matching the patients. However, following anti-TNF therapy, each exhibited a different outcome. In patient 1, the normalization of TNF levels was accompanied by increased IFN-α/β secretion and paradoxical psoriasis (a recently described possible consequence of anti-TNF antibodies [68]), which might require appropriate management (jakinhibs, eventually). On the other hand, patient 2, in which the same treatment also enabled a marked reduction in the circulating TNF level and improvement of joint inflammation, responded by an additional strong decrease in IL-1β expression (as previously described [69]), putting him at risk of developing various microbial infections and therefore requiring specific monitoring in the future. These hypothetical cases indicate that the determination of the cytokinome and its evolution upon treatment might bring substantial benefits to patients with inflammatory diseases.

Figure 3. The multidimensional compass of inflammation. Radar plot showing the hypothetical expression levels of 43 cytokines/chemokines in the Control and two RA patients before and after anti-TNF therapy.
Funding: This work was supported by the Agence Nationale de la Recherche (ANR)-ANR-11-LABX-0070_TRANSPLANTEX, the Institut National de la Santé et de la Recherche Médicale (INSERM), MSD-Avenir grant AUTOGEN, the University of Strasbourg (including IDEX UNISTRA), the European regional development fund (European Union) INTERREG V programs, TRIDIA and PERSONALIS and Fédération Hospitalo-Universitaire (FHU) OMCARE.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: PG thanks Seiamak Bahram (Strasbourg University, France) and Stephan Bluml (Vienna University, Austria) for the critical reading of the manuscript.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Ma, J.; Zhao, S.; Gao, X.; Wang, R.; Liu, J.; Zhou, X.; Zhou, Y. The Roles of Inflammasomes in Host Defense against Mycobacterium tuberculosis. Pathogens 2021, 10, 120. [CrossRef]
2. Schoggins, J.W. Recent advances in antiviral interferon-stimulated gene biology. F1000Research 2018, 7, 309. [CrossRef]
3. Lazear, H.M.; Schoggins, J.W.; Diamond, M.S. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019, 50, 907–923. [CrossRef]
4. Li, S.-F.; Gong, M.-J.; Zhao, F.-R.; Shao, J.-J.; Xie, Y.-L.; Zhang, Y.-G.; Chang, H.-Y. Type I Interferon Signaling in Dendritic Cells Induces Antiviral Interferon Responses. mBio 2018, 9, 2. [CrossRef] [PubMed]
5. Orzalli, M.H.; Smith, A.; Jurado, K.A.; Iwasaki, A.; Garlick, J.A.; Kagan, J.C. An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication. Mol. Cell 2018, 71, 825–840. [CrossRef] [PubMed]
6. Aarreberg, I.D.; Wilkins, C.; Ramos, H.J.; Green, R.; Davis, M.A.; Chow, K.; Gale, M. Interleukin-1beta Signaling in Dendritic Cells Induces Antiviral Interferon Responses. mBio 2018, 9, 2. [CrossRef] [PubMed]
7. Jamilloux, Y.; Henry, T.; Belot, A.; Viel, S.; Fauger, M.; El Jammal, T.; Walzer, T.; Francois, B.; Sève, P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 2020, 19, 102567. [CrossRef] [PubMed]
8. Kawai, T.; Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21, 317–337. [CrossRef] [PubMed]
9. Land, W.G. The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I—Promoting inflammation and immunity. Sultan Qaboos Univ. Med. J. 2015, 15, e9–e21. [CrossRef] [PubMed]
10. Land, W.G. The Role of Damage-Associated Molecular Patterns (DAMPs) in Human Diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ. Med. J. 2015, 15, e157–e170. [PubMed]
11. Gong, T.; Liu, L.; Jiang, W.; Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 2020, 20, 95–112. [CrossRef] [PubMed]
12. Moghaddas, F.; Masters, S.L. Monogenic autoinflammatory diseases: Cytokineopathies. Cytokine 2015, 74, 237–246. [CrossRef] [PubMed]
13. Szmyczak, F.; Colli, M.; Mamula, M.; Evans-Molina, C.; Eizirik, D.L. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Sci. Adv. 2021, 7, eabd7600. [CrossRef] [PubMed]
14. Batista, A.F.; Rody, T.; Forny-Germano, L.; Cerdeiro, S.; Bellio, M.; Ferreira, S.; Munoz, D.P.; De Felice, F.G. Interleukin-1beta mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-beta oligomers. J. Neuroinflam. 2021, 18, 54. [CrossRef] [PubMed]
15. Mariotte, A.; De Cauwer, A.; Po, C.; Abou-Faycal, C.; Pichot, A.; Paul, N.; Aouadi, I.; Carapito, R.; Frisch, B.; Macquin, C.; et al. A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of IL-1beta as relevant therapy for gout patients. Theranostics 2020, 10, 2158–2171. [CrossRef] [PubMed]
16. Nehmar, R.; Alsaleh, G.; Saferding, V.; Mariotte, A.; Puchner, A.; Niederreiter, B.; Vandamme, T.; Schabbauer, G.; et al. Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis. Arthritis Rheumatol. 2017, 69, 2124–2135. [CrossRef] [PubMed]
17. Isaacs, A.; Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B. Biol. Sci. 1957, 147, 258–267. [CrossRef]
18. Duncan, C.J.; Randall, R.E.; Hambleton, S. Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity. Trends Genet. 2021, 37, 46–58. [CrossRef] [PubMed]
19. Reich, N.C. Too much of a good thing: Detrimental effects of interferon. Semin. Immunol. 2019, 43, 101282. [CrossRef] [PubMed]
20. Melki, I.; Rose, Y.; Uggenti, C.; Van Eyck, L.; Frémond, M.-L.; Kitabayashi, N.; Rice, G.I.; Jenkinson, E.M.; Boulai, A.; Jeremiah, N.; et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J. Allergy Clin. Immunol. 2017, 140, 543–552.e5. [CrossRef]
21. Volpi, S.; Insalaco, A.; Caorsi, R.; Santori, E.; Messia, V.; Sacco, O.; Terheggen-Lagro, S.; Cardinale, F.; Scarselli, A.; Pastorino, C.; et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J. Clin. Immunol. 2019, 39, 476–485. [CrossRef]
22. Kretschmer, S.; Lee-Kirsch, M.A. Type I interferon-mediated autoinflammation and autoimmunity. Curr. Opin. Immunol. 2017, 49, 96–102. [CrossRef]
23. Savic, S.; Caseley, E.A.; McDermott, M.F. Moving towards a systems-based classification of innate immune-mediated diseases. Nat. Rev. Rheumatol. 2020, 16, 222–237. [CrossRef]
24. Gupta, S.; Kaplan, M.J. Bite of the wolf: Innate immune responses propagate autoimmunity in lupus. J. Clin. Investig. 2021, 131, e144918. [CrossRef][PubMed]
25. Bennett, L.; Palucka, A.K.; Arce, E.; Cantrell, V.; Borvak, J.; Banchereau, J.; Pascual, V. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood. J. Exp. Med. 2003, 197, 711–723. [CrossRef]
26. Mai, L.; Asaduzzaman, A.; Noamani, B.; Fortin, P.R.; Gladman, D.D.; Touma, Z.; Urowitz, M.B.; Wither, J. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res. 2021, 23, 29. [CrossRef]
27. Nehar-Belaid, D.; Hong, S.; Marches, R.; Chen, G.; Bolisetty, M.; Baisch, J.; Walters, L.; Punaro, M.; Rossi, R.J.; Chung, C.-H.; et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat. Immunol. 2020, 21, 1094–1106. [CrossRef][PubMed]
28. Morand, E.F.; Furie, R.; Tanaka, Y.; Bruce, I.N.; Askaneze, A.D.; Richez, C.; Bae, S.-C.; Brohawn, P.Z.; Pineda, L.; Berglind, A.; et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020, 382, 211–221. [CrossRef][PubMed]
29. Italiani, P.; Manca, M.L.; Angelotti, F.; Melillo, D.; Pratesi, F.; Puxeddu, I.; Boraschi, D.; Migliorini, P. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res. 2018, 20, 27. [CrossRef]
30. Cafarelli, F.; Coladonato, L.; Lopalco, G.; Cacciapaglia, F.; Cantarini, L.; Iannone, F. Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2020, 39, 227.
31. Kubler, L.; Bittmann, I.; Kuipers, J.G. Macrophage activation syndrome triggered by active systemic lupus erythematosus: Successful treatment by interleukin-1 inhibition (anakinra). Z. Rheumatol. 2020, 79, 1040–1045. [CrossRef][PubMed]
32. Malik, A.; Kanneganti, T.-D. Inflammasome activation and assembly at a glance. J. Cell Sci. 2017, 130, 3955–3963. [CrossRef]
33. Sönnmez, H.E.; Özen, S. A clinical update on inflammasomopathies. Int. Immunol. 2017, 29, 393–400. [CrossRef][PubMed]
34. Malcova, H.; Strizova, Z.; Milota, T.; Striz, I.; Sediva, A.; Cebeaucerova, D.; Horvath, R. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives. Front. Immunol. 2021, 11, 619257. [CrossRef][PubMed]
35. Pennisi, M.; Crupi, R.; Di Paola, R.; Ontario, M.L.; Bella, R.; Calabrese, E.J.; Crea, R.; Cuzzocrea, S.; Calabrese, V. Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NLRP3 in Alzheimer disease. J. Neurosci. Res. 2017, 95, 1360–1372. [CrossRef]
36. Camilli, G.; Bohm, M.; Piffer, A.C.; Lavenir, R.; Williams, D.L.; Neven, B.; Grateau, G.; Georgin-Lavialle, S.; Quintin, J. Beta-Glucan-induced reprogramming of human macrophages inhibits NLRP3 inflammasome activation in cryopyrinopathies. J. Clin. Investig. 2020, 130, 4561–4573. [CrossRef]
37. Dilger, R.N.; Johnson, R.W. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 2020, 87, 932–939. [CrossRef][PubMed]
38. Musella, A.; Fresegna, D.; Rizzo, F.R.; Gentile, A.; De Vito, F.; Caioli, S.; Guadalupi, L.; Bruno, A.; Dolcetti, E.; Buttari, F.; et al. ‘Prototypical’ proinflammatory cytokine (IL-1) in multiple sclerosis: Role in pathogenesis and therapeutic targeting. Expert Opin. Targets 2020, 24, 37–46. [CrossRef]
39. McGinley, P.M.; Goldschmidt, C.H.; Rae-Grant, A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 2021, 325, 765–779. [CrossRef]
40. Chisari, C.G.; Sgarlata, E.; Arena, S.; Toscano, S.; Luca, M.; Patti, F. Rituximab for the treatment of multiple sclerosis: A review. J. Neuro. 2021, 1–25.
41. Masanneck, L.; Eichler, S.; Vogelsang, A.; Korsen, M.; Wiendl, H.; Budde, T.; Meuth, S.G. The STING-IFN-beta-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. Int. J. Mol. Sci. 2020, 21, 9249. [CrossRef][PubMed]
42. Guarda, G.; Braun, M.; Staehli, F.; Tardivel, A.; Mattmann, C.; Förster, I.; Farlik, M.; Deckter, T.; Du Pasquier, R.A.; Romero, P.; et al. Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. Immunity 2011, 34, 213–223. [CrossRef][PubMed]
43. Mayer-Barber, K.D.; Yan, B. Clash of the Cytokine Titans: Counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell. Mol. Immunol. 2017, 14, 22–35. [CrossRef][PubMed]
44. Ludigs, K.; Parfenov, V.; Du Pasquier, R.A.; Guarda, G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell. Mol. Life Sci. 2012, 69, 3395–3418. [CrossRef][PubMed]
45. Van Kempen, T.S.; Wenink, M.H.; Leijten, E.F.; Radstake, T.R.; Boes, M. Perception of self: Distinguishing autoimmunity from autoinflammation. Nat. Rev. Rheumatol. 2015, 11, 483–492. [CrossRef][PubMed]
46. Malhotra, S.; Costa, C.; Eixarch, H.; Keller, C.W.; Amman, L.; Martínez-Banaclocha, H.; Midaglia, L.; Sarró, E.; Machín-Díaz, I.; Villar, L.M.; et al. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain 2020, 143, 1414–1430. [CrossRef]
47. Piancone, F.; Saresella, M.; Marventano, I.; La Rosa, F.; Santangelo, M.A.; Caputo, D.; Mendozzi, L.; Rovaris, M.; Clerici, M. Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. *Front. Immunol.* **2018**, *9*, 983. [CrossRef]

48. Nehmar, R.; Mariotte, A.; De Cauwer, A.; Sibilia, J.; Bahram, S.; Georgel, P. Therapeutic Perspectives for Interferons and Plasmacytoid Dendritic Cells in Rheumatoid Arthritis. *Trends Mol. Med.* **2018**, *24*, 338–347. [CrossRef]

49. Kohase, M.; Zhang, Y.; Lin, J.X.; Yamazaki, S.; Sehgal, P.B.; Vílček, J. Interleukin-1 can inhibit interferon-beta synthesis and its antiviral action: Comparison with tumor necrosis factor. *J. Interferon. Res.* **1988**, *8*, 559–570. [CrossRef]

50. SSlim, J.; Afridi, M.S. Managing Adverse Effects of Interferon-Alfa and Ribavirin in Combination Therapy for HCV. *Drugs* **2007**, *67*, 2187–2210. [CrossRef]

51. Wągstań, J.A.; Perry, C.M. Topical imiquimod: A review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. *Drugs* **2007**, *67*, 2187–2210. [CrossRef]

52. Tanaka, Y.; Tummal, R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. *Mod. Rheumatol.* **2021**, *31*, 1–12. [CrossRef] [PubMed]

53. Clere-Jehl, R.; Mariotte, A.; Meziani, F.; Bahram, S.; Georgel, P.; Helms, J. JAK–STAT Targeting Offers Novel Therapeutic Opportunities in Sepsis. *Trends Mol. Med.* **2020**, *26*, 987–1002. [CrossRef]

54. Melki, I.; Frémond, M.-L. Type I Interferonopathies: From a Novel Concept to Targeted Therapies. *Curr. Rheumatol. Rep.* **2020**, *22*, 32. [CrossRef] [PubMed]

55. Bassi, G.; Grimaudo, M.; Panseri, S.; Montesi, M. Advanced Multi-Dimensional Cellular Models as Emerging Reality to Reproduce Cell Carcinoma and Other Skin Lesions. *Bioinformation* **2010**, *6*, 74, 801–815. [CrossRef] [PubMed]

56. Mailhot, B.; Christin, M.; Tessandier, N.; Sotoudeh, C.; Bretheau, F.; Turmel, R.; Pellerin, È.; et al. Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases. *J. Exp. Med.* **2020**, *227*, 217. [CrossRef] [PubMed]

57. Lin, C.C.; Edelson, B.T. New Insights into the Role of IL-1 beta in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. *J. Immunol.* **2017**, *198*, 4535–4560. [CrossRef]

58. Ozdogan, H.; Ugurlu, S.; Uygunoglu, U.; Tutuncu, M.; Gul, A.; Akman, G.; Siva, A. The efficacy of anti-IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. *Mult. Scler. Relat. Disord.* **2019**, *45*, 102332. [CrossRef]

59. Iula, L.; Keitelman, I.A.; Sabbione, F.; Bretheau, F.; Turmel, R.; Pellerin, È.; et al. Human monocyte-derived macrophages inhibit HCMV spread independent of classical antiviral cytokines. *Cytokine* **2018**, *101*, 189–196. [CrossRef] [PubMed]

60. Esnault, S.; Kelly, E.A.; Nettenstrom, L.M.; Cook, E.B.; Seroogy, C.M.; Joly-Beauparlant, C.; et al. Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases. *J. Exp. Med.* **2020**, *227*, 217. [CrossRef] [PubMed]

61. Wagstaff, J.A.; Perry, C.M. Topical imiquimod: A review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. *Drugs* **2007**, *67*, 2187–2210. [CrossRef]

62. Becker, J.; Kinast, V.; Döring, M.; Lipps, C.; Duran, V.; Spanier, J.; Tegtmeyer, P.-K.; Wirth, D.; Cicin-Sain, L.; Alcam, E. Heterogeneity of the cytokinome in undifferentiated arthritis progressing to rheumatoid arthritis and predict requirement for subsequent biological therapy: Results from the pathobiology of early arthritis cohort (PEAC). *Mod. Rheumatol.* **2020**, *30*, 1642–1650. [CrossRef] [PubMed]

63. Brennan, F.; Jackson, A.; Chantry, D.; Maini, R.; Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. *Lancet* **1989**, *2*, 244–247. [CrossRef] [PubMed]